Beyond Deworming: The Evolving Challenge of Parasite Resistance and New Parasiticide Strategies in the US Equine Sector
While parasite control has always been a fundamental component of equine husbandry, the US equine healthcare sector is currently grappling with the major challenge of anthelmintic resistance—the reduced effectiveness of traditional deworming medications. This resistance, often driven by overuse or improper rotation of products, necessitates a fundamental shift in parasite management strategy.
The modern approach now relies heavily on diagnostics, specifically Fecal Egg Count (FEC) testing, to create highly individualized, evidence-based deworming programs. This targeted strategy moves away from the calendar-based, rotational dosing of the past, focusing instead on identifying high egg-shedders and treating only the animals that truly need it, thereby slowing the development of widespread resistance.
In response to this critical need, pharmaceutical companies are heavily investing in the research and development of novel parasiticides and combination products that can effectively treat resistant internal and external parasites, including tapeworms and encysted small strongyles. The combination of smarter diagnostic testing with innovative therapeutic agents defines the future of effective parasite control within this essential health segment. Access more specialized data on this application in the US Equine Healthcare report.
FAQ
Q: What is anthelmintic resistance? A: Anthelmintic resistance is the ability of parasites, like internal worms, to survive the doses of deworming medication (parasiticides) that were previously effective.
Q: How is Fecal Egg Count (FEC) testing used in modern parasite control? A: FEC testing determines the parasite burden in an individual horse, allowing veterinarians to prescribe a targeted deworming schedule only for those horses that require treatment, which helps slow resistance.